2025
Immune inhibitory receptor agonist therapeutics
Lovewell R, Langermann S, Flies D. Immune inhibitory receptor agonist therapeutics. Frontiers In Immunology 2025, 16: 1566869. PMID: 40207220, DOI: 10.3389/fimmu.2025.1566869.Peer-Reviewed Original ResearchConceptsAgonist suppressionSurface of immune cellsCheckpoint inhibitorsStimulatory cellsStimulatory receptorsSuppressive cellsDysregulated inflammationImmune cellsPre-clinicalTreat diseasesDisease settingsAgonistsImmune systemImmune pathwaysClinical therapeuticsTherapeutic interventionsDiseaseReceptorsCellular levelTherapeuticsCellsPathwayInduced signalsAutoimmunityInflammation
2020
Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer
Alvero AB, Hanlon D, Pitruzzello M, Filler R, Robinson E, Sobolev O, Tedja R, Ventura A, Bosenberg M, Han P, Edelson RL, Mor G. Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer. OncoImmunology 2020, 9: 1758869. PMID: 32566387, PMCID: PMC7302442, DOI: 10.1080/2162402x.2020.1758869.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerSyngeneic mouse modelOvarian cancerRecurrent diseaseMouse modelRecurrent high-grade serous ovarian cancerEffective anti-tumor immune responseDendritic cell vaccination strategiesHuman cutaneous T cell lymphomaAnti-tumor immune responseMyeloid-derived suppressive cellsCutaneous T-cell lymphomaIntra-peritoneal tumorsWhole tumor antigenChemotherapy-resistant diseaseFirst-line standardT-cell lymphomaOvarian cancer accountsSerous ovarian cancerTumor-associated macrophagesImmunotherapeutic interventionsGynecologic malignanciesSuppressive cellsDisease coursePatient survival
2019
Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer.
Jayakumar A, Bothwell ALM. Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer. The Journal Of Immunology 2019, 203: 1095-1103. PMID: 31427398, PMCID: PMC6703177, DOI: 10.4049/jimmunol.1900500.Peer-Reviewed Original ResearchConceptsRegulatory B cellsRegulatory T cellsT cellsB cellsSuppressor cellsIL-17-producing T cellsAntitumor T cellsB cell functionHost immune responseAbility of MDSCsAttractive immunotherapeutic targetDifferent tumor modelsMDSC functionSuppressive cellsIL-17Tumor cell survivalImmunotherapeutic targetImmunological nicheImmune responseTumor growthTumor modelCancer typesMDSCsCell functionMyeloid
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply